Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
IL-35 (human):Fc (LALA-PG)-KIH (human) (rec.)
440
CHF
CHF 440.00
In stock
AG-40B-0252-C05050 µgCHF 440.00
Figure 1: Protein structure of IL-35 (human):Fc (LALA-PG)-KIH (human) (rec.) (Prod. No. AG-40B-0252) containing a single heterodimer.
| Product Details | |
|---|---|
| Synonyms | InVivoKine™; Interleukin-35 (human):Fc Knobs-into-Holes (human) (rec.); IL-12 Subunit α; EBI3; Interleukin-27 Subunit β; Ebi3; Epstein-Barr Virus-induced Gene 3 Protein Homolog |
| Product Type | Protein |
| Properties | |
| Source/Host | HEK 293 cells. Produced using animal component-free medium. |
| Sequence |
IL-12Ap35 (aa 23-219) (human):Fc (LALA-PG) Knobs and IL-27B/EBI3 (aa 21-229) (human):Fc (LALA-PG) Holes form the IL-35 (human):Fc (LALA-PG)-KIH (human) (rec.) using the Knobs-into-Holes technology (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). |
| Crossreactivity | Human |
| Specificity |
Binds to human IL-35 receptor complex. Fc (LALA-PG)-KIH (human) does not bind to FcRs. |
| MW | ~68kDa and 60 kDa (SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.005 EU/μg purified protein (LAL test). |
| Concentration | 1mg/ml after reconstitution. |
| Reconstitution | Reconstitute with 50μl endotoxin-free water. |
| Accession Number | P29459 / Q14213 |
| Formulation | Lyophilized. Contains PBS |
| Protein Negative Control |
Fc (LALA-PG)-KIH (human) IgG1 Control (rec.) (Prod. No. AG-35B-0018) |
| Other Product Data |
UniProt link P29459: IL-12A (human) UniProt link Q14213: IL-27B /Ebi3 (human) |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Interleukin-12 (IL-12) family members are heterodimer glycoproteins, composed of two covalently linked subunits, α and β chains. The α-subunit consists of IL-23p19, IL-27p28, and IL-12p35 and the β-subunit includes IL-12p40 and Epstein-Barr virus-induced gene (Ebi3). IL-12 members bind to cognate heterodimeric receptor chains expressed on T cells.
This family includes IL-12, IL-23, IL-27 and IL-35 and IL-39. IL-12 and IL-23 are predominantly proinflammatory cytokines that contribute key roles in the development of Th1 and Th17 cells, respectively. IL-27 has both pro- and anti-inflammatory properties and is a potent T cell immunomodulator. IL-35, a new member of this family, is a potent inhibitory cytokine produced by natural, thymus-derived regulatory T cell (nTreg) populations. Recently, a subset of B cells that produce IL-35 was identified and shown to provide protection against autoimmune diseases. These IL-12 family members link innate immunity with the development of adaptive immunity and are also important for regulating T cell responses.
IL-35 is composed of two subunits, IL-12A and Epstein-Barr virus-induced gene 3 (EBI3) signals via a heterodimeric receptor consisting of IL-12Rβ2 and glycoprotein (gp130), leading to activation of STAT 1 and 4. IL-35 is a potent suppressive cytokine directly limiting the inflammatory response that has important roles in infection, cancer and autoimmune diseases.
The protein IL-35 (human):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IL-12A:Fc Knobs sequence (synthesizing a protein of 68kDa) and one encoding for the IL27B/EBI3:Fc Holes sequence (synthesizing a protein of 60kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein IL-35 (human):Fc (LALA-PG)-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcγRs and C1q while FcRn binding and Fc stability remain unaffected.
InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.
Related Products
